{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:47:37Z","timestamp":1755218857289,"version":"3.43.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Non-Hodgkin\u2019s lymphomas are the eighth-most prevalent malignancy in females and the eleventh in males. No research has been conducted comparing dexamethasone, cytarabine cisplatin (DHAP) vs. ifosfamide, carboplatin, etoposide (ICE) as salvage chemotherapy regimens for relapsed or refractory lymphomas in Pakistan. This study aims to compare the response of ICE vs. DHAP as salvage chemotherapy in patients with relapsed\/refractory lymphomas.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A prospective follow-up study was conducted at the tertiary care hospital in Karachi, Pakistan, from 2019 to 2020. A total of 58 lymphoma patients after first-line chemotherapy were included in the study. The treatment response was evaluated after two cycles of salvage chemotherapy using WHO assessment criteria, and Cox regression was used to determine the hazard ratios considering the <jats:italic toggle=\"yes\">P<\/jats:italic> value \u22640.05 significant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of 58 patients, 19 (32.8%) patients achieved complete response (CR), and 8 (13.8%) patients achieved partial response (PR), with an overall response rate of overall response rate of 46.6%. In the ICE group, the response was assessed in 19 patients. Overall response was 42.1%, CR was 31.6% and PR was 10.5%. In the DHAP group, response was evaluated in 39 patients, the overall response rate was 48.7%, CR was 33.3% and PR was 15.4%. The hazard ratio for survival in patients with relapsed\/refractory lymphomas who received DHAP was 1.40 times (95% CI: 1.27\u20133.63, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.001) compared to patients who received ICE as salvage chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>DHAP seems to have a marginally better overall response rate than the ICE regimen in patients with refractory or relapsed lymphoma. However, the toxicity profile of patients in both groups was similar.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ms9.0000000000000956","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T06:09:05Z","timestamp":1693980545000},"page":"4256-4261","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Response to ifosfamide, carboplatin, etoposide (ICE) vs. dexamethasone, cytarabine cisplatin (DHAP) as salvage chemotherapy in patients with relapsed\/refractory lymphoma"],"prefix":"10.1097","volume":"85","author":[{"given":"Kanta","family":"Devi","sequence":"first","affiliation":[{"name":"Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salman Muhammad","family":"Soomar","sequence":"additional","affiliation":[{"name":"Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Usman","family":"Shaikh","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, Aga Khan University Hospital, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Ali","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, Aga Khan University Hospital, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,9]]},"reference":[{"key":"R1-20250806","doi-asserted-by":"crossref","first-page":"977","DOI":"10.19045\/bspab.2019.80039","article-title":"Epidemiological features of Lymphoma in Pakistan","volume":"8","author":"Shabbir","year":"2019","journal-title":"Pure Appl Biol"},{"key":"R2-20250806","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1200\/EDBK_175444","article-title":"Health disparities and the global landscape of lymphoma care today","volume":"37","author":"Phillips","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R3-20250806","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s12185-018-2430-6","article-title":"Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia\/lymphoma in Japan","volume":"107","author":"Miyoshi","year":"2018","journal-title":"Int J Hematol"},{"key":"R4-20250806","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.hemonc.2016.12.002","article-title":"Relapse of Hodgkin lymphoma after autologous transplantation: time to rethink treatment?","volume":"10","author":"Jethava","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"R5-20250806","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4999\/uhod.161143","article-title":"Retrospective analysis of toxicity profiles of two platinum-based salvage regimens in relapsed\/refractory lymphoma: DHAP versus ESHAP","volume":"26","author":"Salim","year":"2016","journal-title":"Int J Hematol Oncol"},{"key":"R6-20250806","doi-asserted-by":"crossref","first-page":"896","DOI":"10.2967\/jnumed.111.087460","article-title":"Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission","volume":"52","author":"Buchegger","year":"2011","journal-title":"J Nucl Med"},{"key":"R7-20250806","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2967\/jnumed.115.166280","article-title":"Response assessment criteria and their applications in lymphoma: Part 1","volume":"57","author":"Moghbel","year":"2016","journal-title":"J Nucl Med"},{"key":"R8-20250806","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4103\/2277-9175.201687","article-title":"Comparison of ifosfamide, carboplatin and etoposide versus etoposide, steroid, and cytarabine cisplatin as salvage chemotherapy in patients with refractory or relapsed Hodgkin\u2019s lymphoma","volume":"6","author":"Mehrzad","year":"2017","journal-title":"Adv Biomed Res"},{"key":"R9-20250806","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1600-0609.2006.00796.x","article-title":"Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas","volume":"78","author":"Sch\u00fctt","year":"2007","journal-title":"Eur J Haematol"},{"key":"R10-20250806","doi-asserted-by":"crossref","first-page":"100430","DOI":"10.1016\/j.ijso.2021.100430","article-title":"Strocss 2021: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery","volume":"37","author":"Mathew","year":"2021","journal-title":"Int J Surg Open"},{"key":"R11-20250806","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15761\/HMO.1000144","article-title":"Gemcitabine-vinorelbine-prednisolone combination in cases with lymphoma: retrospective analysis","volume":"2","author":"Paydas","year":"2017","journal-title":"Hematol Med Oncol"},{"key":"R12-20250806","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/2040620717728000","article-title":"Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma","volume":"8","author":"Nikolaenko","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"R13-20250806","first-page":"1","article-title":"Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study","volume":"5","author":"Tan","year":"2020","journal-title":"Sig Transduct Target Ther"},{"key":"R14-20250806","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/07357900701788098","article-title":"Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma","volume":"26","author":"Abali","year":"2008","journal-title":"Cancer Invest"},{"key":"R15-20250806","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1200\/EDBK_238799","article-title":"Relapsed and refractory classical Hodgkin lymphoma: keeping pace with novel agents and new options for salvage therapy","volume":"39","author":"Moskowitz","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R16-20250806","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bjh.15412","article-title":"How I manage patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"182","author":"Gisselbrecht","year":"2018","journal-title":"Br Jf Haematol"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000000956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:03:20Z","timestamp":1754485400000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000000956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":16,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000000956","relation":{},"ISSN":["2049-0801"],"issn-type":[{"type":"electronic","value":"2049-0801"}],"subject":[],"published":{"date-parts":[[2023,7,26]]},"assertion":[{"value":"2023-04-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}